PURPOSE: We assess the efficacy of intravesical administration of oxybutynin chloride in patients with interstitial cystitis. MATERIALS AND METHODS: The study included 36 women with a mean age of 45 years with a diagnosis of interstitial cystitis. Patients were treated with gradual intravesical instillation of saline oxybutynin solution (oxybutynin group) or gradual filling of simple saline (control group). Evaluation parameters consisted of symptom problem index, voids per day, volume per void, functional bladder capacity, volume at first sensation, cystometric bladder capacity and cystometric volume at first sensation. RESULTS: Statistically significant improvement of all evaluated parameters was found in both groups. When comparing the outcomes statistically significant improvement of parameters favored the oxybutynin group. CONCLUSIONS: Bladder training alone produces a satisfactory result by gradually expanding the bladder, and an additional statistically significant improvement is evident with intravesical oxybutynin.
RCT Entities:
PURPOSE: We assess the efficacy of intravesical administration of oxybutynin chloride in patients with interstitial cystitis. MATERIALS AND METHODS: The study included 36 women with a mean age of 45 years with a diagnosis of interstitial cystitis. Patients were treated with gradual intravesical instillation of saline oxybutynin solution (oxybutynin group) or gradual filling of simple saline (control group). Evaluation parameters consisted of symptom problem index, voids per day, volume per void, functional bladder capacity, volume at first sensation, cystometric bladder capacity and cystometric volume at first sensation. RESULTS: Statistically significant improvement of all evaluated parameters was found in both groups. When comparing the outcomes statistically significant improvement of parameters favored the oxybutynin group. CONCLUSIONS: Bladder training alone produces a satisfactory result by gradually expanding the bladder, and an additional statistically significant improvement is evident with intravesical oxybutynin.
Authors: Carolina Pazin; Andréia Moreira de Souza Mitidieri; Ana Paula Moreira Silva; Maria Beatriz Ferreira Gurian; Omero Benedicto Poli-Neto; Julio Cesar Rosa-E-Silva Journal: Int Urogynecol J Date: 2015-08-14 Impact factor: 2.894
Authors: Mari Imamura; Neil W Scott; Sheila A Wallace; Joseph A Ogah; Abigail A Ford; Yann A Dubos; Miriam Brazzelli Journal: Cochrane Database Syst Rev Date: 2020-07-30
Authors: Jordan Dimitrakov; Kurt Kroenke; William D Steers; Charles Berde; David Zurakowski; Michael R Freeman; Jeffrey L Jackson Journal: Arch Intern Med Date: 2007-10-08
Authors: Darryl T Martin; Jill M Steinbach; Jingchun Liu; Shogo Shimizu; Hristos Z Kaimakliotis; Marcia A Wheeler; Adam B Hittelman; W Mark Saltzman; Robert M Weiss Journal: Mol Cancer Ther Date: 2013-11-12 Impact factor: 6.261